A single poorly designed clinical trial can cost pharmaceutical companies hundreds of millions of pounds, years of development time or, in some cases, prevent a new treatment from ever reaching patients.
‘Virtual twins’ aim to prevent avoidable trial failures by allowing sponsors to test, refine and optimise trial designs before they begin. This reduces risk, accelerates timelines and supports innovation across the pharmaceutical ecosystem.
The concept of a virtual twin is rooted in product life cycle management, historically used to design complex products such as aircraft.
Check out the rest of the feature here
